The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute effective treatment for ulcerative colitis. ⋯ Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis. (Funded by Millennium Pharmaceuticals; GEMINI 1 ClinicalTrials.gov number, NCT00783718.).